EUVIMEDEUVIMED entdecken
Crossref

ZFP36 reverses chemoresistance by disrupting lipid droplets accumulation in non-small cell lung cancer

Zhe Wang, Peng Hou, Yang Wu, Jiaojiao Dai, Ping Zhao, Xiaoxun Cheng, Zhengze Hu, Lingling Zhang, Jinghan Hua

Cellular Signalling · 2025-12 · 136 · 112119

DOI: 10.1016/j.cellsig.2025.112119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2025-12. Verfasst von Zhe Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Anhui Medical University; Institute of Clinical Pharmacology, Anhui Medical University; Key Laboratory of Anti-inf…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Lipid Droplets. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Anhui Province Department of Education, Anhui Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired chemoresistance is a major factor contributing to non-small cell lung cancer (NSCLC) therapy failure, and there is no effective intervention target. Recent evidence suggests that disrupting the altered lipid metabolism could sensitize cancer cells to chemotherapy treatments. Here, we demonstrate that zinc finger protein 36 (ZFP36) downregulation promotes the accumulation of lipid droplets (LDs) through the ZFP36-mediated fatty acid synthase (FASN) mRNA decay process, contributing to NSCLC progression and the acquisition of chemoresistance. We advocate that enhancing the suppressive role of ZFP36 on LDs accumulation to treat chemoresistant NSCLC, based on its novel regulatory mechanism in chemoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsLipid DropletsTristetraprolinHumansCell Line, TumorFatty Acid Synthase, Type IAnimalsRNA StabilityGene Expression Regulation, NeoplasticMice

Stichwörter der Autor:innen

ChemoresistanceFASNLDsNSCLCZFP36

Substanzen

TristetraprolinZFP36 protein, humanFatty Acid Synthase, Type IFASN protein, human

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Anhui Medical University; Institute of Clinical Pharmacology, Anhui Medical University; Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, An…
  • High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences; University of Science and Technology of China, Hefei 230026, Anhui, China.
  • The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China.
  • The Second Clinical School of Anhui Medical University, Hefei 230032, Anhui, China.

Förderung

  • Anhui Province Department of Education
  • Anhui Medical University

Zitieren

APA

Wang, Z., Hou, P., Wu, Y., Dai, J., Zhao, P., Cheng, X., Hu, Z., Zhang, L., & Hua, J. (2025). ZFP36 reverses chemoresistance by disrupting lipid droplets accumulation in non-small cell lung cancer. Cellular Signalling, 136, 112119. https://doi.org/10.1016/j.cellsig.2025.112119

Vancouver

Wang Z, Hou P, Wu Y, Dai J, Zhao P, Cheng X, et al. ZFP36 reverses chemoresistance by disrupting lipid droplets accumulation in non-small cell lung cancer. Cellular Signalling. 2025;136:112119. doi:10.1016/j.cellsig.2025.112119

BibTeX
@article{Wang2025,
  author = {Wang, Zhe and Hou, Peng and Wu, Yang and Dai, Jiaojiao and Zhao, Ping and Cheng, Xiaoxun and Hu, Zhengze and Zhang, Lingling and Hua, Jinghan},
  title = {ZFP36 reverses chemoresistance by disrupting lipid droplets accumulation in non-small cell lung cancer},
  journal = {Cellular Signalling},
  year = {2025},
  volume = {136},
  pages = {112119},
  doi = {10.1016/j.cellsig.2025.112119}
}
Kostenlos starten →